North America Antibiotics & Antimycotics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The North America antibiotics & antimycotics market size is expected to reach US$ 24,726.59 million by 2031 from US$ 16,434.34 million in 2023. The market is estimated to record a CAGR of 5.2% from 2023 to 2031.

Executive Summary and North America Antibiotics & Antimycotics Market Analysis:

The North American antibiotics and antimycotics market is driven by rising incidences of infectious diseases, increased awareness about antimicrobial resistance, and ongoing pharmaceutical research. Key players continue to invest in innovative formulations and combination therapies. Regulatory support and advanced healthcare infrastructure also support market growth. Despite challenges like resistance and strict approval processes, the demand for effective antimicrobial treatments remains steady, particularly in hospital settings and among immunocompromised populations.

North America Antibiotics & Antimycotics Market Strategic Insights

Get more information on this report Request Free Sample PDF

North America Antibiotics & Antimycotics Market Segmentation Analysis

Key segments that contributed to the derivation of the North America antibiotics & antimycotics market analysis are drug class, indication, route of administration, and distribution channel.

• Based on drug class, the North America antibiotics & antimycotics market is segmented into penicillin, cephalosporines, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. The penicillin held the largest share of the market in 2023.
• Based on indication, the North America antibiotics & antimycotics market is segmented into skin infections, respiratory infections, urinary tract infections (UTI), septicemia, ear infections, gastrointestinal infections, and others. The skin infections held the largest share of the market in 2023.
• Based on route of administration, the North America antibiotics & antimycotics market is segmented into oral, topical, and others. The oral held the largest share of the market in 2023.
• Based on distribution channel, the North America antibiotics & antimycotics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies held the largest share of the market in 2023.

North America Antibiotics & Antimycotics Market Outlook

The growing awareness of fungal infections and their significant health impacts, coupled with initiatives by government and private organizations, is a crucial factor contributing to the antibiotics and antimycotics market growth. The global burden of invasive fungal infections (IFIs) is attributed to their high morbidity and mortality rates, particularly among immunocompromised patients, such as those undergoing chemotherapy or living with HIV/AIDS. According to the Global Action Fund for Fungal Infections (GAFFI) 2023, more than 300 million people worldwide suffer from serious fungal diseases, resulting in approximately 1.5 million deaths annually—more than the combined deaths from malaria and tuberculosis. Such an upsurge in the prevalence of fungal infections has led to increased efforts in mass education and diagnosis, leading to extensive knowledge among healthcare providers and patients about the importance of timely intervention. Innovations in diagnostic techniques such as molecular testing have further enabled the early diagnosis of fungal pathogens, further driving the demand for effective antifungal treatments.

The Centers for Disease Control and Prevention (CDC) implemented programs such as surveillance against Candida aureus in April 2024, enhancing laboratory capabilities, leveraging data to take action, and managing outbreaks. A 10-year road map for the elimination of fungal illnesses was created by the Global Action Fund for Fungal Infections (GAFFI) in 2015, which also outlines the fundamental conditions required for efficient diagnostic delivery. Similarly, the International Society for Human and Animal Mycology (ISHAM), European Centre for Disease Prevention and Control (ECDC), Mycoses Study Group (MSGERC), Asia Fungal Working Group, Fungal Infection Trust, British Mycology Society, and International Mycological Association are among other associations that make efforts to underline the burden of fungal infections, aiding in the prevention, diagnoses, and treatment of these diseases. Every year, September 16–20 is observed as the Fungal Disease Awareness Week (FDAW) to raise awareness of the growing prevalence of fungal illnesses around the world and the need for appropriate action. Such efforts made to bolster the understanding of fungal diseases result in a surge in diagnoses and the number of patients requiring care, which encourages research aimed at developing new and effective antimycotics.

North America Antibiotics & Antimycotics Market Country Insights

Based on country, the North America antibiotics & antimycotics market comprises the US, Canada, and Mexico. The US held the largest share in 2023.

In North America, the US holds a significant share of the antibiotics & antimycotics market. The US antibiotics and antimycotics market growth is driven by the increasing prevalence of fungal and bacterial infections and the growing need for effective treatment options. Pneumonia is the most common respiratory infection in the US. According to Verywell Health Journal 2024 report, every year, ~1.5 million adults in the US are diagnosed with pneumonia; of which around 1 million are admitted to hospitals while 50,000 people die due to pneumonia or related complications. Amoxicillin and azithromycin are the most commonly used antibiotics prescribed in the US in outpatient settings for the treatment of bacterial infections. In addition, with ongoing advancements in pharmaceutical research and technology, the development of new antibiotics and antifungal agents has gained momentum, responding to the growing concerns about antibiotic resistance and the need for innovative therapies. Moreover, the growing awareness about the importance of antimicrobial stewardship programs has led to a more cautious approach to antibiotic prescription, prompting a shift toward targeted therapies and combination treatments. This is particularly evident in hospital settings, where the growing incidence of hospital-acquired infections necessitates the use of potent antimicrobials.

Key players are taking strategic initiatives such as product launches, product approvals, and collaborations, which are expected to support the market growth during the forecast period. For instance, in April 2024, the US Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults suffering from Staphylococcus aureus bloodstream infections (SAB), including those with right-sided infective endocarditis and adults suffering from acute bacterial skin and skin structure infections (ABSSSI). Additionally, in March 2023, The US FDA approved REZZAYO (rezafungin for injection) for the treatment of candidemia and invasive candidiasis.

North America Antibiotics & Antimycotics Market Report Highlights

North America Antibiotics & Antimycotics Market Company Profiles

Some of the key players operating in the market are Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Antibiotics & Antimycotics Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

North America Antibiotics & Antimycotics Market Country and Regional Insights